A biotechnology enterprise focused on health innovations, diagnostics, therapeutics, and platform technologies, leveraging licensing, acquisitions, and partnerships.

# Company Overview and Operations Summary

## What the Company Does
The company is a biotechnology enterprise focused on harnessing large stakeholder ecosystems to accelerate the development, socialization, and commercialization of health innovations. Its core approach involves licensing or acquiring promising health-related innovations, building subsidiaries around each, and supporting them across various operational functions to bring them to market effectively. The company's primary focus areas include immune health, precision health, population health, women’s health, and neurologic health.

### Core Business Model Components
- **Securing an Innovation:** License or acquire health innovations from research institutions, government agencies, private organizations.
- **Growing an Innovation:** Support innovations with resources in areas such as operations, commercialization, finance, content, engagement, personnel, and administration.
- **Monetizing an Innovation:** Develop innovations into self-sustainable, commercial-stage products that create shareholder value by partnering with researchers, medical institutions (e.g., Mayo Clinic), manufacturing partners, municipalities, and public health agencies.

### Key Programs and Innovations
- **Adimune:** Focuses on immune modulation therapies, initially developing ADI-100 for autoimmune diseases like psoriasis, type 1 diabetes, and CNS autoimmune disorders such as stiff-person syndrome. Uses nucleic acid-based technology mimicking natural immune tolerance.
- **Pearsanta:** Specializes in precision medicine diagnostics, particularly early detection of cancer and other diseases via mitochondrial DNA biomarkers and DNA adduct analysis. Acquired assets include Mitomic® platform for mitochondrial DNA biomarker discovery, aiming at cancer screenings such as prostate, ovarian, and lung cancers, and conditions like endometriosis.
- **Adivir:** Focuses on antiviral and anti-infective products for population health, including an antiviral medication, Avigan®, licensed from Cellvera G Response Aid FZE.
- **Technology Licensing:** Holds licenses such as AditxtScore™ from Stanford (personal immune system profiling) and licensed nucleic acid technology from Loma Linda University.

### Infrastructure
- Operates a state-of-the-art, CLIA-certified and CAP-accredited laboratory in Richmond, VA, equipped for rapid development of diagnostic and therapeutic tests.
- Developed a broad portfolio of diagnostic products and platform technologies including digital PCR, real-time PCR, automated DNA/RNA processing, and mass-tag enhancements.

## Company Size and Financials
- **Employees:** 26 full-time employees as of December 31, 2024.
- **Revenue:** No significant revenue from commercial sales to date.
- **Net Losses:** 
  - 2024: **$35,020,058**
  - 2023: **$32,390,447**
- **Accumulated Deficit (as of December 31, 2024):** **$168,094,569**

## Summary
The company develops and commercializes health diagnostics, therapeutics, and platform technologies through licensing, acquisitions, and partnerships. Its current operations span innovative immune modulation therapies, early disease detection diagnostics based on mitochondrial DNA, and antiviral population health products, supported by a global network of research institutions, healthcare providers, and manufacturing partners.

Aditxt, Inc. is a health innovation company focused on transforming promising health technologies into commercially viable products through collaboration and strategic partnerships.

# Company Overview: Aditxt, Inc.

## Mission
Aditxt, Inc. is dedicated to harnessing the collaborative power of stakeholders to accelerate the commercialization of promising health innovations. The company's mission is to transform inventions into impactful products and services that address major health challenges.

## Business Model
Aditxt operates under a three-part business model:
1. **Securing Innovations**: Acquiring or licensing innovations from a variety of sources, such as research institutions, government agencies, and private organizations.
2. **Growing Innovations**: Providing resources for development, including innovation, operations, commercialization, finance, and personnel.
3. **Monetizing Innovations**: Aiming for each innovation to become commercially viable and financially self-sustaining.

## Key Programs
Aditxt has formed several subsidiaries to focus on specific health innovations, including:

### 1. Adimune, Inc.
- **Focus**: Immune modulation therapies aimed at treating autoimmune diseases and enhancing organ transplant acceptance.
- **Key Product**: ADI-100™, a proprietary therapy currently in preclinical and clinical trial phases, partnering with Mayo Clinic for clinical studies.
- **Advantages**: Aimed to reduce adverse effects associated with traditional immunosuppressants.

### 2. Pearsanta, Inc.
- **Focus**: Personalized health diagnostics through a platform termed “Health by the Numbers.”
- **Technologies**: Lab quality testing that integrates telemedicine, sample collection, and rapid point-of-care results.
- **Market Opportunity**: Targeting a clinical and consumer diagnostic market expected to reach $429.3 billion by 2030.

### 3. Adivir, Inc.
- **Focus**: Development of antiviral and other anti-infective products.
- **Key Asset**: Acquired exclusive rights to the antiviral medication Avigan® 200mg (with certain geographic exclusions).

## Financial Overview
- **Revenue**: The company has **generated no significant revenue** from commercial sales to date.
- **Losses**: The net losses for the years ended December 31, 2023, and 2022, were **$32,390,447** and **$27,549,876**, respectively.
- **Accumulated Deficit**: As of December 31, 2023, the accumulated deficit was **$127,635,389**.
- **Employees**: As of December 31, 2023, Aditxt had **47 full-time employees**.

## Customer Base
While the specific number of customers is not detailed, Aditxt engages multiple stakeholders across various sectors, including:
- Research institutions (e.g., Stanford University, Mayo Clinic).
- Health institutions involved in clinical trials.
- Government and public health agencies.
- Thousands of shareholders globally.

## Operations and Infrastructure
Aditxt has developed an extensive infrastructure comprising:
- **Clinical Laboratory**: Based in Richmond, Virginia, certified under CLIA for high-complexity testing.
- **Partnerships**: Established global access to leading research institutions, manufacturers, and distribution companies.

## Summary
Aditxt, Inc. is focused on innovating in the health sector through a collaborative model that effectively brings promising technologies to market. Despite not generating significant revenue so far, the company continues to build its portfolio of health innovations with a team of experienced professionals and strategic partnerships aimed at transforming healthcare through personalized medicine and advanced diagnostics.

Aditxt, Inc.

10-K / March 31, 2025

10-K / April 16, 2024

10-K / March 31, 2025

Company Overview and Operations Summary

What the Company Does

Core Business Model Components

Key Programs and Innovations

Infrastructure

Company Size and Financials

Summary